Compares two surgeries to lower ovarian cancer risk in high-risk women
Tests removing the fallopian tubes first, with later ovary removal, in women with gene changes.
Plain-language title generated from the registry record
Registry title: TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Key facts
- Where
- Nordbyhagen, Oslo, and Stavanger, NorwaySee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 50 years old?
- Have you ever been told you have ovarian, fallopian tube or peritoneal cancer?
Source: NCT04294927, who can take part
Where in Norway
- Akershus University HospitalNordbyhagen, NorwayNo longer taking part
- Oslo University HospitalOslo, NorwayTaking people
- Stavanger Uniersity HospitalStavanger, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Medical Center Nijmegen
- Trial code
- NCT04294927
- Record updated
- 6 April 2026
- Original description
The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.Read full original descriptionShow less
TUBectomy With Delayed Oophorectomy as Alternative for Risk-reducing Salpingo-oophorectomy in High Risk Women to Assess the Safety of Prevention: TUBA-WISP II Study.
The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.
Inclusion: Women with a class 5 (definitely pathogenic) BRCA1, BRCA2, RAD51C, RAD51D or BRIP1 germline mutation in one of the participating centers; Age at inclusion; BRCA1: 25-40 years; BRCA2: 25-45 years; RAD51C, RAD51D, BRIP1: 25-50 years; Childbearing completed; Presence of at least one fallopian tube; Participants may have a personal history of non-ovarian malignancy; Informed consent must be obtained and documented according to national and local regulatory requirements and the local rules followed in the institution.
Exclusion: Prior bilateral salpingectomy; A personal history of ovarian, fallopian tube or peritoneal cancer; Current diagnosis or treatment for malignant disease; Postmenopausal status (natural menopause or due to treatment); Wish for second stage RRO within two years after RRS; Legally incapable.